Delivering the Future of Oligonucleotide Therapies

TargoPep uses its next-generation platform to design, research and refine targeted neurological delivery solutions for oligonucleotide therapeutics.

TargoPep is a specialist in the delivery of oligotherapeutics

Our biological and chemical expertise, patented chemical solutions and innovative design principles enable our bespoke, peptide-based delivery systems to provide tailored drug delivery. Our technology overcomes barriers often associated with the clinical application of oligonucleotide-based therapeutics.

Enabling the greater proliferation of oligo treatments for neurological disorders

Current delivery solutions rely on non-ideal and clinically limiting methods, which are expensive, time-consuming to adapt and are holding back discovery and the development of treatment options.

Our modular, dynamic and versatile approach enables TargoPep to address these neuro-delivery needs and expand the possibilities for oligonucleotide cures into the clinic.

Enabling the greater proliferation of oligo treatments for neurological disorders

Current delivery solutions rely on non-ideal and clinically limiting methods, which are expensive, time-consuming to adapt and are holding back discovery and the development of treatment options.

Our modular, dynamic and versatile approach enables TargoPep to address these neuro-delivery needs and expand the possibilities for oligonucleotide cures into the clinic.

Creating transformative therapies to change patients’ lives now

Our development pipeline is focused on providing bespoke and targeted delivery solutions to treat Neurofibromatosis type 1 (NF1) and Parkinson’s disease.

Currently under-served by treatment options, TargoPep will deliver therapies to create a real-world difference to people’s lives.

Partner with TargoPep...

Augmenting your therapeutic pipeline with TargoPep’s unique delivery technologies can accelerate those therapies into the clinic.

TargoPep’s modularity and diversity of potential solutions provides multiple options for partners to explore.

Latest news

With the increasing number of gene therapies hitting the market, this segment of the biotech industry must be approaching an inflection point and a related spurt in value growth…read our latest short article to find out more.

Following a successful round in the Scottish EDGE entrepreneurship competition semi-final… TargoPep is thrilled to be going forward as a finalist!

Dr. Fergus McWhinnie, TargoPep’s CSO, looks at the story of oligotherapeutic approaches, the current success stories and the direction of research in the field that will provide future cures to today’s ‘uncurable’ diseases.